BR112022018929A2 - Inibidores da ciclofilina e seus usos - Google Patents

Inibidores da ciclofilina e seus usos

Info

Publication number
BR112022018929A2
BR112022018929A2 BR112022018929A BR112022018929A BR112022018929A2 BR 112022018929 A2 BR112022018929 A2 BR 112022018929A2 BR 112022018929 A BR112022018929 A BR 112022018929A BR 112022018929 A BR112022018929 A BR 112022018929A BR 112022018929 A2 BR112022018929 A2 BR 112022018929A2
Authority
BR
Brazil
Prior art keywords
cyclophilin inhibitors
inhibitors
cyclophilin
organ
cyclophiline
Prior art date
Application number
BR112022018929A
Other languages
English (en)
Inventor
Mak Ching-Pong
Ma Fashu
Peel Michael
Fliri Hans
Original Assignee
Farsight Medical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Tech Shanghai Co Ltd filed Critical Farsight Medical Tech Shanghai Co Ltd
Publication of BR112022018929A2 publication Critical patent/BR112022018929A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

INIBIDORES DA CICLOFILINA E SEUS USOS. Os compostos definidos pela Fórmula 4 são utilizados como inibidores da ciclofilina, para a prevenção ou o tratamento de doenças ou distúrbios, tais como a lesão de um órgão ou a falência de um órgão.
BR112022018929A 2020-03-26 2021-03-25 Inibidores da ciclofilina e seus usos BR112022018929A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020081295 2020-03-26
CN2021078391 2021-03-01
PCT/CN2021/083013 WO2021190601A1 (en) 2020-03-26 2021-03-25 Cyclophilin inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112022018929A2 true BR112022018929A2 (pt) 2022-12-06

Family

ID=77891510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018929A BR112022018929A2 (pt) 2020-03-26 2021-03-25 Inibidores da ciclofilina e seus usos

Country Status (12)

Country Link
US (2) US20230174583A1 (pt)
EP (2) EP4126905A4 (pt)
JP (2) JP2023518777A (pt)
KR (2) KR20220158761A (pt)
CN (2) CN115298199A (pt)
AU (1) AU2021240762A1 (pt)
BR (1) BR112022018929A2 (pt)
CA (2) CA3172535A1 (pt)
IL (1) IL296586A (pt)
MX (1) MX2022011697A (pt)
TW (1) TW202144379A (pt)
WO (2) WO2021190604A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
GB202207348D0 (en) * 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof
WO2024183651A1 (en) * 2023-03-03 2024-09-12 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of agent‐induced liver conditions or diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
KR100585348B1 (ko) * 1997-10-08 2006-06-01 이소테크니카 인코포레이티드 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도
EP1086124B1 (en) 1998-06-12 2003-11-19 C-Chem AG Novel cyclosporins
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
ZA200703157B (en) * 2004-10-01 2008-08-27 Scynexis Inc 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
BRPI0516737A (pt) 2004-10-01 2008-04-29 Scynexis Inc método para tratamento ou prevenção da infecção pelo vìrus da hepatite c, usos de um derivado de ciclosporina e de 3-[(r) -2- (n,n-dimetilamino) etiltio-sar] -4- (gama-hidroximetileucina) ciclosporina, ou um sal farmaceuticamente aceitável deste, sal farmaceuticamente aceitável do derivado de ciclosporina, e, hidrato
DK2023918T3 (da) * 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
EP2307446A4 (en) 2008-07-30 2012-11-07 Isotechnika Pharma Inc NON-IMMUNOSUPPRESSIVE CYCLOSPORINE ANALOGOUS MOLECULES
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CN103153329A (zh) * 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
US9890198B2 (en) * 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
HUE042490T2 (hu) 2010-12-15 2019-07-29 Contravir Pharmaceuticals Inc 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
EP2908841A4 (en) * 2012-10-19 2016-05-25 Scynexis Inc NEW ANTIVIRAL MACROCYCLES
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
WO2017004304A1 (en) * 2015-06-30 2017-01-05 Cypralis Limited Novel macrocycles
CN106902346A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技（武汉）有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技（武汉）有限公司 亲环孢素抑制剂的用途
EP3458470A4 (en) 2016-05-17 2020-04-22 S&T Global Inc. NEW CYCLOSPOR DERIVATIVES AND USES THEREOF
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途

Also Published As

Publication number Publication date
KR20220158760A (ko) 2022-12-01
CA3172535A1 (en) 2021-09-30
JP2023518776A (ja) 2023-05-08
EP4126904A4 (en) 2024-05-29
JP2023518777A (ja) 2023-05-08
EP4126904A1 (en) 2023-02-08
CN115298199A (zh) 2022-11-04
WO2021190601A1 (en) 2021-09-30
KR20220158761A (ko) 2022-12-01
MX2022011697A (es) 2022-10-07
EP4126905A4 (en) 2024-05-29
CA3172601A1 (en) 2021-09-30
IL296586A (en) 2022-11-01
TW202144379A (zh) 2021-12-01
AU2021240762A1 (en) 2022-10-06
US20230174583A1 (en) 2023-06-08
EP4126905A1 (en) 2023-02-08
US12060440B2 (en) 2024-08-13
CN115335389A (zh) 2022-11-11
US20230110497A1 (en) 2023-04-13
WO2021190604A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
BR112022018929A2 (pt) Inibidores da ciclofilina e seus usos
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2021005987A2 (es) Compuestos de anillo fusionado
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112021017620A2 (pt) Compostos macrocíclicos
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
BR112022011917A2 (pt) Fluoroalquil-oxadiazois e seus usos
SV2010003491A (es) 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112022004802A2 (pt) Moduladores de il-17a e usos dos mesmos
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
BR112019004254A2 (pt) inibidores da dopamina-b-hidroxilase penetrantes da barreira hematoencefálica
BR112023016614A2 (pt) Inibidores de tyk2 e usos dos mesmos
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
BR112023016678A2 (pt) Inibidores de tyk2 e usos dos mesmos